Drug safety alert: CDSCO flags 58 drug samples

Published On 2024-04-02 11:36 GMT   |   Update On 2024-04-02 11:36 GMT

In its latest drug safety alert, the apex drug regulatory body, the Central Standard Control Organisation (CDSCO) has flagged 58 medicine batches for failing to qualify for a random sample test for February 2023, while 2 drug samples have been declared as suprious.These drugs include Acepik - P (Aceclofenac and Paracetamol Tablets) manufactured by Nexkem Biotech, Amoxycillin Oral Suspension...

Login or Register to read the full article

In its latest drug safety alert, the apex drug regulatory body, the Central Standard Control Organisation (CDSCO) has flagged 58 medicine batches for failing to qualify for a random sample test for February 2023, while 2 drug samples have been declared as suprious.

These drugs include Acepik - P (Aceclofenac and Paracetamol Tablets) manufactured by Nexkem Biotech, Amoxycillin Oral Suspension I.P. (Medmoxil 125) manufactured by Laborate Pharmaceuticals, Calcium Carbonate and Vitamin D3 Tablets IP (Calcigiant 500 Tablets) manufactured by Nutra Life Healthcare, Ofloxacin manufactured by Concept Pharmaceutical, Calcium and Vitamin D3 Tablets manufactured by Hanuchem Laboratories, Serratiopeptidase Tablets manufactured by Arnav Research Laboratories.

For more information, click on the link below:


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News